Aimed Bio Inc.
June 18, 2025
Company Presentation
Oncology
153C
Founded in 2018 as a spin-off from Samsung Medical Center, AimedBio is a clinical-stage biotech company specializing in antibody-drug conjugates (ADCs) and antibody-based cancer therapies. The company stands out by integrating patient-derived data and samples throughout its development process, improving drug precision and clinical relevance. Through collaboration with clinicians, AimedBio targets high-priority medical needs and uses clinical and public data to identify effective gene targets. Its proprietary antibody panning method with patient-derived cells (PDCs) enhances ADC precision, reduces trial attrition, and improves predictions of drug efficacy and safety—accelerating development timelines.
Company HQ City:
Seoul
Company HQ State:
Seoul-t'ukpyolsi
Company HQ Country:
Korea, Republic of
Year Founded:
2018
Lead Product in Development:
AMB303 (Potential Best-in-class ROR1 ADC with Topo-1; DAR 8)
AMB304 (Potential Best-in-class CDCP1 ADC with site specific conjugation on Glycan with Topo-1 inhibitor; DAR 4)
CEO
Nam-Gu Her
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
- Signing of subsequent pipeline technology transfer agreement (expected end of May 2025)
- Acquire technology evaluation rating for KOSDAQ listing (within June 2025)
What is your next catalyst (value inflection) update?
Refer to answers in question 7.
Website
aimedbio.com
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}